RT Journal Article SR Electronic T1 FBXO22 deficiency defines a pleiotropic syndrome of growth restriction and multi-system anomalies associated with a unique epigenetic signature JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.09.28.24314530 DO 10.1101/2024.09.28.24314530 A1 Ramakrishna, Navin B. A1 Johmura, Yoshikazu A1 Ali, Nur Ain A1 Mohamad Sahari, Umar Bin A1 Alghamdi, Malak A1 Bauer, Peter A1 Khan, Suliman A1 Ordoñez, Natalia A1 Ferreira, Mariana A1 Pinto Basto, Jorge A1 Alkuraya, Fowzan S. A1 Faqeih, Eissa Ali A1 Mori, Mari A1 Almontashiri, Naif A. M. A1 Al Shamsi, Aisha A1 ElGhazali, Gehad A1 Abu Subieh, Hala A1 Al Ojaimi, Mode A1 El-Hattab, Ayman W. A1 Al-Kindi, Said Ahmed Said A1 Alhashmi, Nadia A1 Alhabshan, Fahad A1 Al Saman, Abdulaziz A1 Tfayli, Hala A1 Arabi, Mariam A1 Khalifeh, Simone A1 Taylor, Alan A1 Alfadhel, Majid A1 Jain, Ruchi A1 Sinha, Shruti A1 Shenbagam, Shruti A1 Ramachandran, Revathy A1 Altunoğlu, Umut A1 Jacob, Anju A1 Thalange, Nandu A1 Shin, Jay W. A1 Al-Maawali, Almundher A1 Al-Shidhani, Azza A1 Al-Futaisi, Amna A1 Rabea, Fatma A1 Chekroun, Ikram A1 Al Marri, Mohamed A1 Ohta, Tomohiko A1 Nakanishi, Makoto A1 Alsheikh-Ali, Alawi A1 Ali, Fahad R. A1 Bertoli-Avella, Aida M. A1 Reversade, Bruno A1 Abou Tayoun, Ahmad YR 2024 UL http://medrxiv.org/content/early/2024/10/01/2024.09.28.24314530.abstract AB FBXO22 encodes an F-box protein which acts as a substrate-recognition component of the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase complex. Despite its known roles in the post-translational ubiquitination and degradation of specific substrates, including histone demethylases, the impact of FBXO22 on human development remains unknown. Here, we characterize a pleiotropic syndrome with prominent prenatal onset growth restriction and notable neurodevelopmental delay across 14 cases from 12 families. Through exome and genome sequencing, we identify three distinct homozygous loss-of-function FBXO22 variants segregating with the disease: p.(Arg53Serfs*13), p.(Pro3Leufs*3) and p.(Val240Alafs*6), all predicted to lead to premature translation termination due to frameshift effects. We confirm that patient-derived primary fibroblasts are bereft of FBXO22 and show increased levels of the known substrate histone H3K9 demethylase KDM4B. Accordingly, we delineate a unique epigenetic signature for this disease in peripheral blood. Altogether, we identify and demonstrate that FBXO22 deficiency leads to a pleiotropic syndrome in humans encompassing growth restriction and neurodevelopmental delay, the pathogenesis of which may be explained by broad chromatin alterations.Competing Interest StatementP.B., S.K., N.O., M.F., J.P.B. and A.M.B.-A. are employees of Centogene GmbH. All other authors declare no conflicts of interest.Funding StatementN.B.R. is a recipient of Singapore Ministry of Health RIE2025 National Medical Research Council OF-YIRG award (OFYIRG23jan-0036, MOH-001341) administered by the Agency for Science, Technology and Research. A.A.M is a recipient of Sultan Qaboos University Strategic research funding (SR/MED/GENT/16/01). B.R. is a fellow of the Branco Weiss Foundation (Switzerland) and an EMBO Young Investigator (Europe) and is funded by BESE at KAUST in the KSA. We would also like to acknowledge the support of the Mohammed Bin Rashid University of Medicine and Health Sciences and Al Jalila Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved and ethical approval for this work was given by the Agency of Science, Technology and Research (A*STAR) IRB (2019-087) in Singapore and at King Abdullah University of Science and Technology (KAUST) IRB (23IBEC090) in the KSA.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data and code parameters that support the findings of this study are detailed within the methods and supplemental information, or from the corresponding authors upon request.